Medication info
Zefazine Duo Tablet 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Zefazine Duo Tablet 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Dark brownish-purple, biconvex, oval film-coated tablet
Packaging
Bottle - 60 tablets/bottle, PTP - 60 tablets/box [(10 tablets/PTP x 6)]
Approval status
Active

MFDS item code 202501820 · Approved 2025.07.17 · Insurance code 645406590

Summary

Main use
Improvement of glycemic control in adult patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose is 1 tablet twice daily. The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients whose glycemic control is inadequate with metformin alone or in combination with other medicines, such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min, provided they do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated using empagliflozin and metformin as separate single-ingredient products. The maximum daily dose of metformin hydrochloride that may be administered using this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adult patients with type 2 diabetes mellitus

  • Abnormal blood sugar control
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes, in conjunction with diet and exercise. It specifically aids in effectively managing blood sugar by combining empagliflozin and metformin. It can also be used in patients whose blood sugar control is insufficient and who have concomitant cardiovascular diseases, in which case, precautions regarding the risk of cardiovascular events must be confirmed. This medication helps with blood sugar control to improve diabetes management.

How to take

Adult dose

The recommended dose is 1 tablet twice daily. The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients whose glycemic control is inadequate with metformin alone or in combination with other medicines, such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min, provided they do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated using empagliflozin and metformin as separate single-ingredient products. The maximum daily dose of metformin hydrochloride that may be administered using this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This drug can cause severe lactic acidosis, so caution is required, especially in patients with poor kidney function or cardiovascular diseases. Additionally, when used with insulin or sulfonylureas, there is a risk of hypoglycemia, so blood glucose levels should be closely monitored. It should not be administered to patients who have allergies to any components included in this drug or have severe renal impairment, acute infections, heart failure, diabetic ketoacidosis, and other specific conditions. Before and after tests using iodinated contrast agents, this medication should be temporarily discontinued and renal function should be checked before resuming. It is safest for pregnant or breastfeeding women to avoid taking this drug. This medication can be affected by kidney function, so regular renal function tests should be performed before and during treatment. Patients at risk of decreased fluid volume, such as those with dehydration, severe diarrhea, or vomiting, need particular attention. During the course of taking this medication, urinary and genital infections may occur; if symptoms of infection arise, immediate consultation with healthcare professionals is advised. Vitamin B12 levels may decrease, so regular blood tests are recommended for those on long-term treatment. Intake of alcohol can increase the risk of lactic acidosis, therefore excessive drinking should be avoided while taking this medication. Elderly individuals may be at increased risk of side effects due to decreased kidney function, thus dosage adjustments and monitoring of kidney function are necessary. This medication can cause hypoglycemia; therefore, especially when taken with insulin or hypoglycemic agents, blood glucose should be checked frequently. During surgery or acute illnesses, it is safer to temporarily discontinue this drug, and then to resume once stable. Attention is needed while driving or operating machinery as the effects of this medication have not been fully verified. While taking this medication, it is essential to regularly monitor health conditions as instructed by a physician and consult immediately if any unusual symptoms appear.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
  • vomiting
Show 90 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvovaginitis
  • balanitis
  • perineal necrosis
  • increased serum creatinine
  • decreased glomerular filtration rate
  • chronic gastritis
  • various gastrointestinal disorders
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuronitis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • insomnia
  • dizziness
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension
  • anxiety

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to preserve its effectiveness.

Appearance and packaging

Appearance

Dark brownish-purple, biconvex, oval film-coated tablet

Package unit

Bottle - 60 tablets/bottle, PTP - 60 tablets/box [(10 tablets/PTP x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.